Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH
Public ClinicalTrials.gov record NCT06104319. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2a, Single Dose, Open-label, Dose Exploration Study to Assess the PK-PD Activity, Safety, and Tolerability of GSK4532990 in Adult. Participants With NASH or Suspected NASH
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to understand how the drug GSK4532990 is processed in the body (pharmacokinetics) and how it works in the liver (pharmacodynamics) as well as to ensure it is safe and well-tolerated. The total study duration for each participant will be approximately 24-36 weeks.
Study identification
- NCT ID
- NCT06104319
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 61 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 22, 2024 (Actual)
- Primary completion
- Sep 23, 2025 (Actual)
- Completion
- Sep 23, 2025 (Actual)
- Last update posted
- Oct 14, 2025
2024 – 2025
United States locations
- U.S. sites
- 14
- U.S. states
- 6
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Chula Vista | California | 91911 | — |
| GSK Investigational Site | Montclair | California | 91763 | — |
| GSK Investigational Site | San Diego | California | 91911 | — |
| GSK Investigational Site | San Diego | California | 91942 | — |
| GSK Investigational Site | Brandon | Florida | 33511 | — |
| GSK Investigational Site | Miami | Florida | 33155 | — |
| GSK Investigational Site | Miami | Florida | 33173 | — |
| GSK Investigational Site | Miami Lakes | Florida | 33014 | — |
| GSK Investigational Site | Indianapolis | Indiana | 46202 | — |
| GSK Investigational Site | El Dorado | Kansas | 67042 | — |
| GSK Investigational Site | Marrero | Louisiana | 70072 | — |
| GSK Investigational Site | Austin | Texas | 78745 | — |
| GSK Investigational Site | San Antonio | Texas | 78215 | — |
| GSK Investigational Site | San Antonio | Texas | 78240 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06104319, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 14, 2025 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06104319 live on ClinicalTrials.gov.